Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients

Sabuncu T., Arikan E., Tasan E., Hatemi H.

INTERNAL MEDICINE, cilt.40, sa.9, ss.857-861, 2001 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 40 Sayı: 9
  • Basım Tarihi: 2001
  • Doi Numarası: 10.2169/internalmedicine.40.857
  • Dergi Adı: INTERNAL MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.857-861
  • Anahtar Kelimeler: dopamine agonist, hyperprolactinemia, prolactinoma, LONG-TERM TREATMENT, DOPAMINE AGONIST, SECRETING MACROADENOMAS, MACROPROLACTINOMA SHRINKAGE, FOLLOW-UP, IN-VIVO, THERAPY, AMENORRHEA, ADENOMECTOMY, MULTICENTER
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Objective It is well known that bromocriptine has a suppressive effect on the prolactin release in hyperprolactinemic patients. But it also has some adverse effects. The new, long-acting dopaminergic drug, cabergoline, has been reported to be an effective agent in these patients. However, there are relatively few reports comparing the beneficial and adverse effects of these drugs in the treatment of hyperprolactinemic patients. Therefore, here we studied and compared the efficacy and tolerability of cabergoline with bromocriptine in hyperprolactinemic patients.